Massachusetts Financial Services Co. MA Buys 4,816 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Massachusetts Financial Services Co. MA lifted its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 3.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 143,523 shares of the company’s stock after buying an additional 4,816 shares during the period. Massachusetts Financial Services Co. MA owned about 0.26% of Voyager Therapeutics worth $1,135,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of VYGR. Ameritas Investment Partners Inc. boosted its holdings in Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after acquiring an additional 1,300 shares during the last quarter. Plato Investment Management Ltd bought a new stake in Voyager Therapeutics in the 1st quarter worth about $38,000. SG Americas Securities LLC purchased a new stake in Voyager Therapeutics in the 2nd quarter valued at about $85,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Voyager Therapeutics by 104.3% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,404 shares of the company’s stock worth $97,000 after buying an additional 5,311 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new stake in shares of Voyager Therapeutics during the first quarter valued at approximately $101,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Stock Performance

VYGR stock opened at $6.25 on Monday. Voyager Therapeutics, Inc. has a fifty-two week low of $5.97 and a fifty-two week high of $11.72. The stock has a fifty day moving average of $7.28 and a 200-day moving average of $8.09. The company has a market capitalization of $339.96 million, a price-to-earnings ratio of -125.00 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.20. The company had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same quarter in the previous year, the firm posted ($0.51) earnings per share. Equities analysts predict that Voyager Therapeutics, Inc. will post -1.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, August 20th. Wedbush cut their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.83.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.